Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display

841 - Evaluation of clinical outcomes of her2/neu positive breast cancer patients treated with adjuvant trastuzumab in two oncology centers from middle income coutries


09 Oct 2016


Poster display


Herman Perroud


Annals of Oncology (2016) 27 (6): 474-482. 10.1093/annonc/mdw387


H.A. Perroud1, C.M. Alasino2, A. Eniu3, N. Antone3

Author affiliations

  • 1 Institute Of Experimental Genetics, School of Medical Sciences, National University of Rosario, 2000 - Rosario/AR
  • 2 Clincal Oncology Department, Italian Hospital of Rosario, 2000 - Rosario/AR
  • 3 Department Of Breast Tumors, Ion Chiricuta Oncology Institute-IOCN, 400015 - Cluj Napoca/RO


Abstract 841


Adjuvant Trastuzumab dramatically reduces the risk of relapse for Her2 positive breast cancer patients (BCP). However, in middle income countries, such as Romania (Ro) and Argentina (Ar), the treatment of HER2 + BCP remains under the constraints of health care resources and poses unique challenges due to lack of resources. The aim of this work is to compare time of initiation of Trastuzumab (TIT) in HER2 + BCP and its correlation with clinical outcome at 5 years in two medical centers: Institute of Oncology "Ion Chiricuta" Cluj-Napoca [Ro] and Hospital Italiano de Rosario [Ar].


This was an observational, retrospective study based on medical records of primary BCP (Hormone receptor [HR], Her2/Neu+) and included 43 patients (n = Ar: 25; Ro: 18) with at least 5 years of follow up from both institutions. According to their clinical outcome (CO) at 5 years of the primary treatment, each patient was classified in two primary groups: disease free or relapsed.


Mean age of patients was 54 (range: 33-91) and mean stage of disease was II (range: I-III). Nonstatistical differences according to age and disease stage were found between groups. The most frequent histology was ductal invasive carcinoma (Ar: 12/25; Ro: 18/18; p = 0.007).All patients received surgery as primary treatment. Fourteen (14) patients received neo-adjuvant treatment (Ar: 7/25; Ro: 7/18; p = 0.167) and twenty two (22) patients received radiotherapy (Ar: 18/25; Ro: 4/18; p = 0.002). Most patients received adjuvant chemotherapy based on anthracyclines schemes (p = 0.139) and all patients received Trastuzumab. Median TIT was 8 months (range: 2-18) [Ar: 7 (range: 2-17); Ro: 11 (range: 4-18), p = 0.001]. At 5 years of follow-up 18 patients relapsed (Ar: 8/25; Ro: 10/18; p = 0.148). There were no association between CO and TIT in both group of patients.


The delay on initiation of Trastuzumab, in our limited series, did not prove to interfere in the risk of relapse in HR-HER2 + BCP. Larger studies are needed to address this issue.

Clinical trial identification

Legal entity responsible for the study



Institute of Experimental Genetics, National University of Rosario, Argentina; Italian Hospital of Rosario, Argentina; and Institute of Oncology "Ion Chiricuta" Cluj-Napoca, Romania.


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings